Biology & drug discovery · New York, US · founded 2023
EvolutionaryScale: who founded it, who funds it
EvolutionaryScale is a New York AI drug discovery lab founded in 2023 by Alex Rives, Tom Sercu and Sal Candido, who came from Meta. What it is building: eSM3 protein language models; the team later joined Biohub. It has raised $142M in disclosed rounds, most recently a Seed of $142M in June 2024, led by Nat Friedman, Daniel Gross and Lux Capital. It has merged into another organisation.
- Founders
- Alex Rives (ex-Meta), Tom Sercu (ex-Meta), Sal Candido (ex-Meta)
- Founders from
- ex-Meta
- Location
- New York, US (North America)
- Valuation
- ·
- Raised
- $142M disclosed
- Investors
- Nat Friedman lead, Daniel Gross lead, Lux Capital lead, Nvidia, Amazon
- What ships
- Merged
Rounds
| Date | Round | Amount | Valuation | Lead | Source |
|---|---|---|---|---|---|
| Jun 25, 2024 | Seed | $142M | · | Nat Friedman, Daniel Gross, Lux Capital | neolabs.fyi |
Sources
- neolabs.fyi neolabs.fyi
News
- Jul 1, 2024
-
Jun 25, 2024
+1 more coverage
- MobiHealthNews AWS partners with EvolutionaryScale following its $142M raise
-
Jun 25, 2024
Investors who back other labs here
- Nvidia also: Safe Superintelligence, Reflection AI, Skild AI, Poolside
- Lux Capital also: Cognition, Physical Intelligence, Applied Compute, Sakana AI
- Amazon also: Odyssey, Dyna Robotics
Same research area
- Chai Discovery $3.8B · San Francisco, US
- Merge Labs $850M · San Francisco, US
- Isomorphic Labs · · London, UK
- Latent Labs · · London, UK
- Xaira Therapeutics · · South San Francisco, US